# Human Rating Form — GDgpt Clinical Utility Evaluation

> **Instructions**: Rate each question on D1-D5 (1=Poor, 3=Adequate, 5=Excellent).
> Fill in the table below. Use same rubric as the LLM judge.
> Return this file after completion.

## Rubric Summary
- **D1 Factual Accuracy**: Are gene/pathway/drug claims correct?
- **D2 Completeness**: Are key evidence items covered?
- **D3 Traceability**: Are claims attributed to specific sources/edges?
- **D4 Clinical Safety**: Does it acknowledge uncertainty vs. fabricate?
- **D5 Coherence**: Is it logically structured and readable?

---
## Question 1: `pcqa_7ec19ce8`
**Q**: What are the targeted drugs for cancers with TP53 mutation?

### System A (GDgpt)
```
Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
Currently, there are no FDA-approved targeted therapies that directly restore or replace the function of mutant TP53. However, several strategies and investigational drugs are being explored:

1. **APR-246 (Eprenetapopt):** This compound reactivates mutant p53 by restoring its wild-type conformation and function. It has shown promise in clinical trials, particularly in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

2. **MDM2 Inhibitors (e.g., Idasanutlin):** These drugs target the p53-MDM2 interaction. While they are effective only in cancers with wild-type TP53, they may have indirect effects if combined with other therapies in mutant TP53 contexts.

3. **PRIMA-1:** A precursor to APR-246, this small molecule also aims to restore mutant p53 function and induce apoptosi
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 2: `pcqa_a97b06ab`
**Q**: What types of cancer can amg-510(racemate) treat?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
AMG 510 (sotorasib), a KRAS G12C inhibitor, is primarily used to treat cancers harboring the KRAS G12C mutation. The types of cancer it has shown clinical efficacy for include:

1. **Non-Small Cell Lung Cancer (NSCLC):** Approved for locally advanced or metastatic NSCLC with a KRAS G12C mutation after prior systemic therapy.
   
2. **Colorectal Cancer (CRC):** Investigational use in metastatic colorectal cancer with KRAS G12C mutations, though responses are generally lower compared to NSCLC.

3. **Other Solid Tumors:** It is under investigation for other KRAS G12C-mutated cancers, such as pancreatic cancers and certain gastrointestinal malignancies, though these are not yet approved indications.

Further evidence may require access to updated clinical trial databases or literature.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 3: `pcqa_5a011ff5`
**Q**: Which types of cancer are related to cancers with EGFR mutations?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
Cancers related to EGFR (epidermal growth factor receptor) mutations include:

1. **Non-Small Cell Lung Cancer (NSCLC)**: EGFR mutations are most commonly associated with adenocarcinoma subtypes of NSCLC, particularly in non-smoking or light-smoking individuals.

2. **Colorectal Cancer (CRC)**: While EGFR overexpression or activation is common, EGFR mutations are rare. However, EGFR signaling plays a role in tumor progression, and anti-EGFR therapies are used in some cases (e.g., wild-type RAS CRC).

3. **Glioblastoma Multiforme (GBM)**: EGFR amplification and mutations (e.g., EGFRvIII variant) are frequently observed.

4. **Head and Neck Squamous Cell Carcinoma (HNSCC)**: EGFR is often overexpressed, though mutations are less frequent compared to amplification or overexpression.

5. **Eso
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 4: `pcqa_3b109123`
**Q**: What are the NMPA-approved drugs for cancers with TNKS mutations?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
As of my knowledge cutoff in October 2023, there are **no NMPA (National Medical Products Administration)-approved drugs specifically targeting cancers with TNKS (Tankyrase) mutations.** Tankyrases (TNKS1 and TNKS2) are enzymes involved in WNT/β-catenin signaling, telomere maintenance, and other cellular processes, and their dysregulation has been implicated in cancer. However, the development of TNKS inhibitors is still largely in preclinical or early clinical stages, and none have yet received regulatory approval specifically for cancers with TNKS mutations in China or globally.

For precise, up-to-date information, consulting clinical trial databases or recent regulatory announcements would be necessary.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 5: `pcqa_ae2f0870`
**Q**: What is the relationship between BRAF gene mutation and the efficacy of osimertinib?

### System A (GDgpt)
```
Lung cancer is ASSOCIATED_WITH the RAF/MAP kinase cascade, a critical pathway for cellular growth and survival, per the knowledge graph (KG: Lung cancer–associated with–RAF/MAP kinase cascade). Mutations in BRAF are INVOLVED_IN hyperactivation of the RAF/MAP kinase cascade, driving oncogenesis (KG: BRAF–involved in–RAF/MAP kinase cascade). Dabrafenib and Encorafenib directly TARGET BRAF, suppressing this pathway (KG: BRAF–target–Dabrafenib; KG: BRAF–target–Encorafenib). Osimertinib TARGETS EGFR mutations, which are upstream regulators of the RAF/MAP kinase cascade, indirectly influencing downstream signaling (KG: Osimertinib–target–EGFR; KG: Lung cancer–associated with–RAF/MAP kinase cascade). However, no KG-supported evidence directly links Osimertinib efficacy to BRAF mutations, suggesti
```

### System B (GPT-4o)
```
The relationship between **BRAF gene mutations** and the efficacy of **osimertinib** is not directly established, as osimertinib is specifically designed to target **EGFR mutations**, particularly the T790M resistance mutation, in non-small cell lung cancer (NSCLC). However, co-occurring BRAF mutations in EGFR-mutant NSCLC may influence disease biology and treatment outcomes.

**Key points:**
1. **Primary Target of Osimertinib**: Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) with high specificity for mutant EGFR, not BRAF-mutated pathways. It works independently of the BRAF mutation status.
   
2. **Co-occurring BRAF Mutations**: In rare cases, **BRAF mutations (e.g., V600E)** can co-exist with EGFR mutations in NSCLC. Such co-occurrence might confer resistance or modify responsiv
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 6: `pcqa_9901d9aa`
**Q**: What are the genetic mutations in esophageal carcinoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.  
```
```

### System B (GPT-4o)
```
Esophageal carcinoma (EC) is broadly classified into esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), with distinct genetic mutation profiles for each subtype:

### Esophageal Squamous Cell Carcinoma (ESCC)
1. **TP53**: The most frequently mutated gene, found in ~90% of cases.
2. **NOTCH1**: Inactivating mutations in ~10-25% of cases, affecting cell differentiation.
3. **PIK3CA**: Activating mutations in ~5-15% of cases, involved in the PI3K/AKT pathway.
4. **NFE2L2 and KEAP1**: Alterations in oxidative stress response pathways.
5. **SOX2 and TP63**: Amplifications promoting squamous cell identity.

### Esophageal Adenocarcinoma (EAC)
1. **TP53**: Mutated in ~50-70% of cases.
2. **CDKN2A (p16)**: Frequently inactivated, impairing cell cycle regulation.
3. **ER
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 7: `pcqa_4f21f3b4`
**Q**: What genetic diseases can be caused by cancers with AR mutations?

### System A (GDgpt)
```
The androgen receptor gene (**AR**) is ASSOCIATED_WITH **breast cancer**, **breast carcinoma**, **breast neoplasm**, **adenocarcinoma of the liver and intrahepatic biliary tract**, and **hepatocellular carcinoma** per the knowledge graph. In **breast cancer**, AR is INVOLVED_IN hormone-sensitive pathways such as **Estrogen-dependent gene expression**, **PIP3 activates AKT signaling**, and the **RAF/MAP kinase cascade**, contributing to tumor progression. In **adenocarcinoma of the liver and intrahepatic biliary tract**, AR is LINKED_TO pathways like **Resolution of Sister Chromatid Cohesion**, **Separation of Sister Chromatids**, and **RHO GTPases Activate Formins**, which may promote genomic instability and metastasis. Additionally, in **hepatocellular carcinoma**, AR mutations are PHENOT
```

### System B (GPT-4o)
```
Androgen receptor (AR) mutations in cancers are most commonly associated with prostate cancer, where they can lead to resistance to androgen deprivation therapy (ADT) or second-generation anti-androgens like enzalutamide and abiraterone. These mutations alter AR function, allowing tumor cells to continue proliferating despite hormonal therapies.

While AR mutations themselves are not typically classified as causing genetic diseases, they can contribute to syndromes or conditions secondary to cancer progression. Examples include:

1. **Castration-Resistant Prostate Cancer (CRPC):** AR mutations are a hallmark of this advanced stage of prostate cancer, where tumors grow despite low androgen levels.
   
2. **Neuroendocrine Prostate Cancer (NEPC):** AR pathway alterations, including mutations,
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 8: `pcqa_5563c5f0`
**Q**: Which types of cancer are related to the JUB gene?

### System A (GDgpt)
```
Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
The **JUB gene** (encoding Ajuba LIM protein) is implicated in various cancers due to its role in processes like cell adhesion, migration, and the Hippo signaling pathway, which regulates cell proliferation and apoptosis. Current evidence links the JUB gene to the following cancer types:

1. **Hepatocellular carcinoma (HCC)**: Dysregulation of JUB has been associated with tumor progression and poor prognosis in HCC, potentially through its interaction with the Hippo pathway.
   
2. **Gastrointestinal cancers**: Altered expression of JUB has been observed in colorectal and gastric cancers, where it may influence tumor growth and metastasis.

3. **Head and neck squamous cell carcinoma (HNSCC)**: JUB has been implicated in tumor cell proliferation and survival in HNSCC.

4. **Breast cancer**:
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 9: `pcqa_17df8118`
**Q**: What types of cancer can meccnu be used to treat?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
MeCCNU (methyl-CCNU or semustine) is a nitrosourea alkylating agent that has historically been used to treat certain types of cancers. It is primarily indicated for:

1. **Brain Tumors**: Including glioblastoma multiforme and other high-grade gliomas.
2. **Hodgkin's Disease**: As part of multi-agent chemotherapy regimens.
3. **Gastrointestinal Cancers**: Specifically stomach and colorectal cancers.

However, MeCCNU is rarely used today due to its significant toxicity, including delayed bone marrow suppression and risks of secondary malignancies, as well as the availability of newer, less toxic agents. Its use may be restricted or replaced in modern clinical practice, and detailed treatment decisions should be guided by current evidence and protocols.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 10: `pcqa_b0e35222`
**Q**: What are the fusion genes in pancreatic neuroendocrine tumor?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Fusion genes in pancreatic neuroendocrine tumors (PanNETs) are rare but have been reported in certain cases, often involving chromosomal rearrangements. Key examples include:

1. **EWSR1-related fusions**:  
   - *EWSR1-ATF1* and *EWSR1-FLI1* fusions have been reported in rare cases of PanNETs. These fusions are more commonly associated with other tumor types but can occur in PanNETs, particularly in cases with atypical histological features.

2. **MEN1-related rearrangements**:  
   - Although not classically categorized as a "fusion gene," MEN1 mutations or deletions are prevalent in PanNETs, and complex genomic rearrangements involving MEN1 are sometimes observed.

3. **TERT fusions**:  
   - Fusions involving the *TERT* promoter region (e.g., *TERT-MIR122* fusions) have been identified
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 11: `pcqa_27a878a1`
**Q**: What types of cancer can be treated with diethylstilbestrol?

### System A (GDgpt)
```
** Diethylstilbestrol is CONTRAINDICATED for **hepatocellular carcinoma**, **hereditary breast ovarian cancer syndrome**, **liver cancer**, and **prostate cancer** per the knowledge graph (KG: Drug→Disease). The knowledge graph confirms that Diethylstilbestrol INTERACTS_WITH genes such as **COMT**, **CYP19A1**, **CYP3A4**, **SLCO1B1**, and **ABCB1**, which are implicated in hormone-sensitive cancers like **breast cancer**, **hereditary breast carcinoma**, and **squamous cell carcinoma of the corpus uteri** (KG: Drug→Gene→Disease). For **hepatocellular carcinoma**, genes such as **ABCB1** and pathways like **Neutrophil degranulation** and **Resolution of Sister Chromatid Cohesion** are ASSOCIATED_WITH the disease (KG: Disease→Gene and Disease→Gene→Pathway). Similarly, for **hereditary breas
```

### System B (GPT-4o)
```
Diethylstilbestrol (DES), a synthetic nonsteroidal estrogen, is occasionally used in the treatment of certain hormone-sensitive cancers. Its primary indications include:

1. **Prostate Cancer**: DES has historically been used to treat advanced or metastatic prostate cancer due to its ability to suppress testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis. This anti-androgenic effect can help slow tumor progression in hormone-sensitive prostate cancer.

2. **Breast Cancer**: In rare cases, DES may be used for postmenopausal women with advanced estrogen receptor (ER)-positive breast cancer, particularly when other therapies have failed. However, its use has largely been supplanted by more modern treatments like selective estrogen receptor modulators (
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 12: `pcqa_57e32c60`
**Q**: What are the fusion genes in inflammatory myofibroblastic tumor?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
Inflammatory myofibroblastic tumors (IMTs) are frequently associated with gene fusions involving **ALK (anaplastic lymphoma kinase)** or other tyrosine kinase genes. The most common fusion genes in IMTs include:

1. **ALK fusions**: Found in approximately 50–60% of IMTs. ALK is fused to various partner genes, such as:
   - **TPM3** (tropomyosin 3)
   - **TPM4** (tropomyosin 4)
   - **CLTC** (clathrin heavy chain)
   - **RANBP2** (RAN-binding protein 2)
   - **FN1** (fibronectin 1)
   - **SEC31A** (SEC31 homolog A)

2. **ROS1 fusions**: ROS1 rearrangements are seen in a subset of ALK-negative IMTs. Common fusion partners include:
   - **TPM3**
   - **TPM4**
   - **FIG** (formiminotransferase cyclodeaminase)

3. **NTRK3 fusions**: Rare but have been reported in some IMTs.

4. **RET fusions**
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 13: `pcqa_cea91e9d`
**Q**: What are the NMPA-approved drugs for cancers with HDAC4 mutations?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
As of my knowledge cutoff in October 2023, there are no drugs specifically approved by the National Medical Products Administration (NMPA) of China that target cancers with **HDAC4 mutations**. However, histone deacetylase (HDAC) inhibitors, such as **vorinostat** (suberoylanilide hydroxamic acid, SAHA) and **romidepsin**, are approved for certain cancers (e.g., T-cell lymphomas) and may have potential relevance depending on the tumor's context and mechanism. HDAC inhibitors typically target broader HDAC family activity rather than specific HDAC mutations like HDAC4.

For HDAC4-mutant cancers, treatment strategies are usually guided by the tumor type, additional molecular alterations, and potential vulnerabilities inferred from preclinical studies. Further exploration of clinical trials or
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 14: `pcqa_04f6292a`
**Q**: What FDA-approved drugs are available to treat cancers with BCL2L1 mutations?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

**BCL2L1**, a gene encoding the anti-apoptotic protein **BCL-X(L)**, is ASSOCIATED_WITH **hepatocellular carcinoma** and related phenotypes such as **abdominal distension** and **abdominal pain** per the knowledge graph. It is INVOLVED_IN the pathway **BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members**, which regulates apoptosis, and is also INVOLVED_IN the pathways **Interleukin-4 and Interleukin-13 signaling** and **RAS processing**, suggesting secondary roles in inflammation and oncogenic signaling. The knowledge graph identifies three compounds — **4'-Fluoro-1,1'-Biphenyl-4-Carboxylic Acid**, 
```

### System B (GPT-4o)
```
As of my knowledge cutoff in October 2023, there are no FDA-approved drugs specifically targeting cancers with **BCL2L1** mutations. However, **BCL2L1** encodes BCL-XL, an anti-apoptotic protein of the BCL-2 family, and inhibitors targeting the broader BCL-2 family, including BCL-XL, are under investigation.

1. **Navitoclax (ABT-263):** Navitoclax is a small-molecule inhibitor that targets BCL-XL and BCL-2. While it is not FDA-approved, it has been investigated in clinical trials for various cancers.

2. **Venetoclax (ABT-199):** Venetoclax is an FDA-approved BCL-2 inhibitor used to treat chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It does not directly inhibit BCL-XL but may have relevance in cancers where BCL-2 is co-expressed or where BCL2L1 mutations shift depe
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 15: `pcqa_3b5e7c2c`
**Q**: What types of cancer can irinotecan be used to treat?

### System A (GDgpt)
```
Irinotecan is ASSOCIATED_WITH lung cancer for off-label use per the knowledge graph (KG: Drug→Disease) and interacts with genes such as BCHE, CYP3A4, UGT1A9, TOP1, and SLCO1B1, which are ASSOCIATED_WITH breast cancer and related conditions, including hereditary breast carcinoma, breast neoplasm, and hereditary breast ovarian cancer syndrome (KG: Drug→Gene→Disease). Additionally, irinotecan interacts with the same set of genes implicated in squamous cell carcinoma of the corpus uteri (KG: Drug→Gene→Disease). For colorectal cancer, irinotecan indirectly interacts with genes such as TP53, MMP9, and PTGS2, which are INVOLVED_IN pathways like Neutrophil degranulation, Degradation of the extracellular matrix, and Interleukin-4 and Interleukin-13 signaling (KG: Disease→Gene→Pathway). While irinot
```

### System B (GPT-4o)
```
Irinotecan is commonly used to treat several types of cancer, particularly those of the gastrointestinal tract. Its primary indications include:

1. **Colorectal Cancer**: Irinotecan is FDA-approved for metastatic colorectal cancer, often in combination with other agents like fluorouracil and leucovorin (e.g., FOLFIRI regimen). It is also used with bevacizumab or EGFR inhibitors (e.g., cetuximab, panitumumab) in certain settings.

2. **Pancreatic Cancer**: Irinotecan is part of the liposomal irinotecan formulation (nal-IRI) used in combination with fluorouracil and leucovorin for metastatic pancreatic cancer, particularly after progression on gemcitabine-based therapy.

3. **Lung Cancer**: Irinotecan may be used off-label for small cell lung cancer (SCLC), often in combination with cisplat
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 16: `pcqa_a70bd321`
**Q**: What are the drug treatment options for non-squamous non-small cell lung cancer?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
Treatment options for non-squamous non-small cell lung cancer (NSCLC) depend on the molecular profile, stage of disease, and patient-specific factors. Below are the main drug treatment categories:

### 1. **Targeted Therapy** (if actionable mutations are identified):
   - **EGFR mutations**: Osimertinib (preferred), erlotinib, gefitinib, afatinib, or dacomitinib.
   - **ALK rearrangements**: Alectinib (preferred), brigatinib, lorlatinib, crizotinib, or ceritinib.
   - **ROS1 rearrangements**: Crizotinib or entrectinib.
   - **BRAF V600E mutation**: Dabrafenib + trametinib.
   - **MET exon 14 skipping mutation**: Capmatinib or tepotinib.
   - **RET rearrangements**: Selpercatinib or pralsetinib.
   - **NTRK fusions**: Larotrectinib or entrectinib.
   - **KRAS G12C mutation**: Sotorasib or a
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 17: `pcqa_62da8b94`
**Q**: What diseases are caused by cancers with AIRE mutations?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
AIRE (Autoimmune Regulator) mutations are not directly causative of specific cancers, but they are primarily associated with autoimmune diseases such as Autoimmune Polyendocrine Syndrome Type 1 (APS-1). This condition results in immune dysregulation due to defective central immune tolerance.

In the context of cancer, AIRE mutations may result in autoimmune-related inflammation, which could theoretically create a pro-tumorigenic environment or increase the risk of malignancies associated with chronic inflammation. However, there is no direct evidence linking AIRE mutations to specific cancers.

Further investigation in the literature or external databases would be required to determine any emerging associations between AIRE mutations and specific malignancies.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 18: `pcqa_6398a0b8`
**Q**: What types of cancer can be treated with proleukin?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
Proleukin (aldesleukin) is a recombinant interleukin-2 (IL-2) immunotherapy primarily approved for the treatment of:

1. **Metastatic Renal Cell Carcinoma (mRCC)** - Proleukin can be used in adult patients with advanced or metastatic renal cell carcinoma.
2. **Metastatic Melanoma (mM)** - It is also approved for use in adult patients with metastatic melanoma.

Proleukin works by stimulating the proliferation and activation of immune cells, such as T lymphocytes and natural killer (NK) cells, to attack cancer cells. Its use is generally limited to patients with good performance status due to its significant toxicity profile.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 19: `pcqa_681db0df`
**Q**: With which forms of cancer is MAP2K1-p.C121S associated?

### System A (GDgpt)
```
MAP2K1 is ASSOCIATED_WITH familial prostate carcinoma, hereditary breast ovarian cancer syndrome, and lung cancer per the knowledge graph. It is INVOLVED_IN critical cancer-related pathways, including the MAP2K and MAPK activation pathway, the MAP3K8 (TPL2)-dependent MAPK1/3 activation pathway, and the Frs2-mediated activation pathway, which are known to regulate cell proliferation, differentiation, and survival. The p.C121S variant of MAP2K1 is [LLM-inferred] to cause constitutive activation of MEK1, leading to continuous downstream MAPK signaling and potentially driving oncogenesis in these cancers. Confidence in this mechanism is MEDIUM due to strong gene-disease and gene-pathway evidence but a lack of mutation-specific validation. The next verification step is to conduct a literature r
```

### System B (GPT-4o)
```
The **MAP2K1 p.C121S mutation** is associated with several cancer types, particularly those driven by aberrant MAPK pathway signaling. This specific gain-of-function mutation leads to constitutive activation of the MEK1 protein, which promotes downstream ERK signaling. It has been identified in the following cancers:

1. **Melanoma** – Frequently observed in BRAF wild-type melanomas, where it contributes to MAPK pathway activation.
2. **Lung Cancer** – Specifically in non-small cell lung cancer (NSCLC), often in tumors lacking other common driver mutations.
3. **Histiocytic Neoplasms** – Such as Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease, where MAPK pathway alterations, including MAP2K1 mutations, are common.
4. **Colorectal Cancer** – Occasionally found in subsets of 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 20: `pcqa_77ab7539`
**Q**: Which types of cancer can be treated with bleomicin?

### System A (GDgpt)
```
Bleomycin targets the DNA repair genes LIG3 and LIG1, which are ASSOCIATED_WITH colorectal cancer, colorectal carcinoma, and colorectal neoplasm per the knowledge graph (KG: Bleomycin–[TARGETS]–LIG3, LIG1; LIG3, LIG1–[ASSOCIATED_WITH]–Colorectal cancer, Colorectal carcinoma, Colorectal neoplasm). Colorectal cancer is further ASSOCIATED_WITH pathways such as Neutrophil degranulation, Interleukin-4 and Interleukin-13 signaling, and Degradation of the extracellular matrix, which are implicated in inflammation, immune response, and tumor invasion (KG: Colorectal cancer–[ASSOCIATED_WITH]–Pathways). Additionally, phenotypic features like autosomal dominant inheritance and hereditary nonpolyposis colorectal carcinoma are ASSOCIATED_WITH colorectal cancer, suggesting genetic predispositions that m
```

### System B (GPT-4o)
```
Bleomycin is a chemotherapeutic agent used to treat several types of cancers, particularly those that are sensitive to its mechanism of action (causing DNA strand breaks). The main cancer types for which bleomycin is used include:

1. **Hodgkin lymphoma** (as part of the ABVD regimen: Adriamycin, Bleomycin, Vinblastine, Dacarbazine).
2. **Testicular cancer** (as part of the BEP regimen: Bleomycin, Etoposide, Cisplatin).
3. **Non-Hodgkin lymphoma** (in select cases, though less common).
4. **Squamous cell carcinomas of the head, neck, and skin** (in specific settings).
5. **Malignant pleural effusion** (as a sclerosing agent for pleurodesis).

Bleomycin is most effective in rapidly dividing cells but carries risks of pulmonary toxicity, which limits its use in some patients. Detailed treatm
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 21: `pcqa_940fd4c7`
**Q**: What disease does a PALB2 gene mutation cause?

### System A (GDgpt)
```
PALB2 is ASSOCIATED_WITH breast cancer, breast carcinoma, and breast neoplasm, as well as familial prostate carcinoma, per the knowledge graph. PALB2 is INVOLVED_IN DNA repair pathways, including Homologous Recombination Repair (HDR), Homologous DNA Pairing and Strand Exchange, and Resolution of D-loop Structures via Holliday Junction Intermediates. Mutations in PALB2 impair HDR, leading to genomic instability—a hallmark of cancer development. In breast cancer, pathways such as estrogen-dependent gene expression (Breast Cancer–Pathway–Estrogen Signaling) and PIP3-activated AKT signaling (Breast Cancer–Pathway–PIP3/AKT) are likely involved in tumor proliferation and survival, interacting with PALB2 dysfunction [LLM-inferred]. PALB2 is also ASSOCIATED_WITH familial prostate carcinoma, but it
```

### System B (GPT-4o)
```
A mutation in the **PALB2** gene is associated with an increased risk of several cancers, primarily:

1. **Hereditary Breast Cancer**: PALB2 mutations are associated with a significantly increased risk of breast cancer, with lifetime risks estimated to be as high as 44% by age 70 in women.

2. **Pancreatic Cancer**: PALB2 mutations are also linked to an elevated risk of pancreatic cancer.

3. **Ovarian Cancer**: There is evidence suggesting PALB2 mutations may modestly increase the risk of ovarian cancer, though the risk is lower compared to breast cancer.

4. **Fanconi Anemia (FA)**: Biallelic (homozygous) mutations in PALB2 can cause Fanconi anemia, a rare genetic disorder characterized by bone marrow failure, increased cancer risk (especially leukemia), and developmental abnormalities.

```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 22: `pcqa_ae72486f`
**Q**: Which types of cancer are associated with MET?

### System A (GDgpt)
```
The MET gene is ASSOCIATED_WITH multiple cancers, including hepatocellular carcinoma, adenocarcinoma of the liver and intrahepatic biliary tract, familial prostate carcinoma, and hereditary breast ovarian cancer syndrome, as confirmed by the knowledge graph. In hepatocellular carcinoma, MET is INVOLVED_IN pathways such as chromosomal regulation (e.g., "Resolution of Sister Chromatid Cohesion," "Separation of Sister Chromatids"), immune modulation (e.g., "Neutrophil degranulation," "Interleukin-4 and Interleukin-13 signaling"), and cytoskeletal remodeling (e.g., "RHO GTPases Activate Formins"), which may drive tumor growth, immune evasion, and metastasis. Phenotypes like abdominal distention and abdominal pain are ASSOCIATED_WITH hepatocellular carcinoma, likely due to tumor burden and infl
```

### System B (GPT-4o)
```
The MET proto-oncogene, which encodes the hepatocyte growth factor receptor (HGFR), is associated with various types of cancer. Dysregulation of MET through mutations, amplifications, overexpression, or fusions can drive tumorigenesis. Key cancer types associated with MET include:

1. **Non-Small Cell Lung Cancer (NSCLC)**:
   - MET exon 14 skipping mutations
   - MET amplification or overexpression

2. **Renal Cell Carcinoma (RCC)**:
   - Papillary subtype is particularly associated with MET mutations and amplifications.

3. **Hepatocellular Carcinoma (HCC)**:
   - MET overexpression is commonly observed.

4. **Gastric Cancer**:
   - MET amplification and overexpression are linked to aggressive phenotypes.

5. **Glioblastoma**:
   - Associated with MET overexpression or amplification.

6.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 23: `pcqa_52fd00e8`
**Q**: What types of cancer is alitretinoin used to treat?

### System A (GDgpt)
```
Alitretinoin targets retinoid receptors (RXRB, RARG, RARB, RARA) and the transporter gene ABCB1, which is ASSOCIATED_WITH several cancers, including breast cancer, breast neoplasm, hereditary breast carcinoma, hereditary breast ovarian cancer syndrome, and squamous cell carcinoma of the corpus uteri, per the knowledge graph. Retinoid receptors are known to regulate cellular differentiation and proliferation, which are commonly dysregulated in cancer, while ABCB1 is implicated in cancer drug resistance via efflux mechanisms. Breast cancer and breast neoplasm are ASSOCIATED_WITH pathways such as Estrogen-dependent gene expression (involving ESR1, BCL2, PGR, CCND1, JUN), RAF/MAP kinase cascade (involving KIT, ERBB2, FGF4, GRIN2D, FGFR2), and Interleukin-4 and Interleukin-13 signaling (involvi
```

### System B (GPT-4o)
```
Alitretinoin is primarily used in oncology for the treatment of **Kaposi sarcoma**, particularly AIDS-related Kaposi sarcoma. It is a retinoid that acts as an agonist of retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating cell differentiation, proliferation, and apoptosis. Alitretinoin is typically applied topically for cutaneous lesions in this setting. It is not commonly used for other cancer types. 

Further evidence for its use in other malignancies would require consultation of current clinical trial databases or literature.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 24: `pcqa_38e32f3c`
**Q**: What targeted drugs can be used for CLIP1 mutation in clear cell carcinoma of the lung?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
As of my knowledge cutoff in October 2023, there are no specific FDA-approved targeted therapies directed at the **CLIP1 mutation** in clear cell carcinoma of the lung. However, the presence of a CLIP1 fusion, particularly **CLIP1-LTK (Lymphocyte-specific protein tyrosine kinase)**, has been described in some cancers, including lung cancer, and may point to **LTK inhibition** as a therapeutic strategy.

Preclinical studies suggest that **ALK/ROS1 inhibitors** such as **crizotinib** or more selective **next-generation LTK inhibitors** (e.g., TPX-0046) could potentially target LTK fusions. These options, however, would typically require further molecular profiling and might only be accessible within clinical trials or on a case-by-case basis via off-label use.

If the mutation or fusion is i
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 25: `pcqa_595431b0`
**Q**: What types of cancer can be treated with pembrolizumab?

### System A (GDgpt)
```
Pembrolizumab is INDICATED_FOR lung cancer (KG: Pembrolizumab–[indication]–lung cancer) and functions as a PD-1 inhibitor, blocking the interaction between PD-1 on T-cells and PD-L1 expressed on tumor cells to restore T-cell-mediated antitumor immune responses [LLM-inferred]. Lung cancer is ASSOCIATED_WITH multiple signaling pathways, including the RAF/MAP kinase cascade (KG: lung cancer–[associated with]–RAF/MAP kinase cascade) and the PI3K/AKT signaling pathway (KG: lung cancer–[associated with]–PI3K/AKT signaling), which regulate tumor progression, immune evasion, and cell proliferation. Genes such as VEGFA (angiogenesis) and EGFR (oncogenic signaling) are also ASSOCIATED_WITH lung cancer (KG: VEGFA/EGFR–[associated with]–lung cancer). However, no direct KG evidence links Pembrolizumab 
```

### System B (GPT-4o)
```
Pembrolizumab (Keytruda), an anti-PD-1 immune checkpoint inhibitor, is FDA-approved for the treatment of multiple cancer types, including:

1. **Non-Small Cell Lung Cancer (NSCLC)** - For metastatic or unresectable NSCLC with PD-L1 expression (≥1%) without EGFR or ALK genomic aberrations.
2. **Small Cell Lung Cancer (SCLC)** - In combination with chemotherapy for extensive-stage disease.
3. **Melanoma** - For unresectable or metastatic melanoma.
4. **Head and Neck Squamous Cell Carcinoma (HNSCC)** - For recurrent or metastatic disease with PD-L1 expression.
5. **Classical Hodgkin Lymphoma (cHL)** - For relapsed or refractory disease.
6. **Primary Mediastinal Large B-Cell Lymphoma (PMBCL)** - For refractory or relapsed disease.
7. **Urothelial Carcinoma** - For locally advanced or metastati
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 26: `pcqa_dec38f32`
**Q**: What is the relationship between BRAF gene mutation and colon cancer?

### System A (GDgpt)
```
Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
The **BRAF gene mutation**, particularly the **BRAF V600E mutation**, is associated with a subset of colorectal cancers (CRCs) and has significant implications for tumor biology, prognosis, and treatment.

### Key Points:
1. **Prevalence**: BRAF mutations occur in approximately **8–12% of colorectal cancers**, with a higher prevalence in right-sided (proximal) colon cancers.

2. **Prognostic Role**:
   - BRAF V600E-mutated CRC is associated with **poor prognosis**, particularly in metastatic settings, due to its aggressive behavior and resistance to standard therapies.
   - Non-V600E BRAF mutations (rare) may have a more favorable prognosis compared to V600E mutations.

3. **Molecular and Pathological Features**:
   - Frequently occurs in tumors with **microsatellite instability (MSI)** or
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 27: `pcqa_6ee354bc`
**Q**: What types of cancer can carmustine (product) treat?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
Carmustine (BCNU) is an alkylating agent used to treat several types of cancers, particularly those involving the central nervous system (CNS) and hematologic malignancies. Its primary indications include:

1. **Primary brain tumors** (e.g., glioblastoma multiforme, astrocytoma, medulloblastoma, and oligodendroglioma).
2. **Hodgkin lymphoma** (as part of combination chemotherapy regimens, particularly in refractory or relapsed cases).
3. **Non-Hodgkin lymphoma** (in specific cases, especially relapsed or refractory disease).
4. **Multiple myeloma** (as part of combination therapy regimens).
5. **CNS metastases** (off-label in certain situations, depending on clinical judgment).

Additionally, carmustine is available in a **wafer formulation (Gliadel®)** for localized treatment of high-grad
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 28: `pcqa_d062247f`
**Q**: What genetic mutations need to be tested before lung?

### System A (GDgpt)
```
** Lung cancer is driven by mutations or alterations in primary oncogenic driver genes, including **EGFR**, **MET**, **ERBB2**, **FGFR2**, and **AKT1**, which are ASSOCIATED_WITH lung cancer and INTERACT_WITH critical pathways such as the **RAF/MAP kinase cascade** and **PI3K/AKT signaling**, promoting tumor growth, proliferation, and survival per the knowledge graph. Secondary genes such as **NOS2**, **ALOX5**, **MMP9**, and **VEGFA** are ASSOCIATED_WITH lung cancer and INTERACT_WITH pathways like **Interleukin-4 and Interleukin-13 signaling** and **Neutrophil degranulation**, contributing to inflammation and angiogenesis, which may aid tumor progression. Additionally, **A2M** is ASSOCIATED_WITH lung cancer and INTERACTS_WITH the **Degradation of the extracellular matrix** pathway, sugges
```

### System B (GPT-4o)
```
Before initiating treatment for lung cancer, especially non-small cell lung cancer (NSCLC), the following genetic mutations and biomarkers should be tested to guide therapy selection:

1. **EGFR (Epidermal Growth Factor Receptor) mutations**: Common activating mutations include exon 19 deletions and L858R point mutations (exon 21). Resistance mutations like T790M and uncommon alterations (e.g., exon 20 insertions) should also be assessed.

2. **ALK (Anaplastic Lymphoma Kinase) rearrangements**: Test for ALK fusions using fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), or next-generation sequencing (NGS).

3. **ROS1 rearrangements**: ROS1 fusions are targetable with specific tyrosine kinase inhibitors (e.g., crizotinib).

4. **BRAF mutations**: Focus on V600E mutation
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 29: `pcqa_e97e0cf9`
**Q**: What are the drug treatment options for bladder urothelial carcinoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
The drug treatment options for bladder urothelial carcinoma depend on the stage of the disease, prior treatments, and molecular profiling. Below is an overview of key therapeutic categories:

### 1. **Platinum-Based Chemotherapy (First-Line)**
   - **Cisplatin-based regimens**: Preferred for cisplatin-eligible patients (e.g., Gemcitabine + Cisplatin or MVAC [Methotrexate, Vinblastine, Adriamycin, Cisplatin]).
   - **Carboplatin-based regimens**: Used for cisplatin-ineligible patients (e.g., Gemcitabine + Carboplatin).

### 2. **Immune Checkpoint Inhibitors (ICIs)**
   - **For cisplatin-ineligible or second-line settings**:
     - **Atezolizumab** (anti-PD-L1)
     - **Pembrolizumab** (anti-PD-1)
   - **Maintenance therapy**:
     - **Avelumab** (anti-PD-L1): Approved as maintenance therapy
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 30: `pcqa_aab6110b`
**Q**: What types of cancer can be treated with everolimus?

### System A (GDgpt)
```
Everolimus is indicated for breast carcinoma, breast neoplasm, hereditary breast carcinoma, and hereditary breast ovarian cancer syndrome, as confirmed by the knowledge graph (e.g., Everolimus–Drug→Disease–Breast Carcinoma, source=MONDO, DrugBank). The drug directly targets the gene MTOR (Everolimus–Drug→Gene–MTOR→Disease), which is associated with these diseases and plays a critical role in cellular growth, proliferation, and survival. Everolimus is metabolized by the enzymes CYP2D6 and CYP3A4 (Everolimus–Drug→Gene–CYP2D6/CYP3A4) and transported by the genes SLCO1B1 and ABCB1 (Everolimus–Drug→Gene–SLCO1B1/ABCB1), influencing its pharmacokinetics. While the knowledge graph does not provide direct pathway-level evidence linking MTOR to PI3K/AKT signaling or other cancer-related pathways, th
```

### System B (GPT-4o)
```
Everolimus is an mTOR inhibitor approved for treating several cancer types, including:

1. **Hormone Receptor-Positive, HER2-Negative Breast Cancer** (in combination with exemestane) in postmenopausal women with advanced disease after failure of nonsteroidal aromatase inhibitors.
2. **Renal Cell Carcinoma (RCC)** in advanced stages after progression on VEGF-targeted therapy.
3. **Neuroendocrine Tumors (NETs)** of pancreatic, gastrointestinal, or lung origin that are well-differentiated, non-functional, and unresectable or metastatic.
4. **Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma** that does not require immediate surgery.
5. **TSC-Associated Subependymal Giant Cell Astrocytoma (SEGA)** that requires therapeutic intervention but is not amenable to surgical resection.

```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 31: `pcqa_0ffadad2`
**Q**: What are the drug treatment options for esophageal squamous cell carcinoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
Drug treatment options for **esophageal squamous cell carcinoma (ESCC)** depend on the stage of the disease, molecular characteristics, and patient factors. Key treatment options include:

1. **Systemic Chemotherapy:**
   - Typical regimens include:
     - **Cisplatin + 5-Fluorouracil (5-FU)**: A standard backbone for ESCC.
     - **Paclitaxel + Carboplatin**: Commonly used, particularly in combination with radiation (definitive chemoradiotherapy).
     - **Docetaxel-based combinations**: Alternative in some cases.

2. **Immunotherapy:**
   - **Checkpoint inhibitors** targeting PD-1/PD-L1 are now standard for advanced/metastatic ESCC:
     - **Nivolumab**: Approved for previously treated advanced ESCC.
     - **Pembrolizumab**: In first-line treatment for PD-L1-positive cases (CPS ≥10) in 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |
